View in EDS HTML Full Text PDF Full Text

The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis.

Saved in:
Bibliographic Details
Title: The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis.
Authors: Yang, Mi (AUTHOR), Cui, Xingxing (AUTHOR), Kong, Di (AUTHOR), Huang, Xincheng (AUTHOR), Zhao, Guocheng (AUTHOR), Li, Xiuying (AUTHOR), Zhao, Huachang (AUTHOR), Liu, Liju (AUTHOR), Yan, Fei (AUTHOR), Yang, Yan (AUTHOR), Li, Zezhi (AUTHOR)
Source: European Archives of Psychiatry & Clinical Neuroscience. Aug2025, Vol. 275 Issue 5, p1437-1451. 15p.
Subjects: Lactobacillus, Bifidobacterium, Medical practice, Probiotics, Schizophrenia, Randomized controlled trials, Gut microbiota
Abstract: The modulation of gut microbiota through probiotics holds promise as a novel avenue for schizophrenia treatment. This study aims to analyze probiotic complementary therapy on individuals with schizophrenia systematically, to investigate probiotic efficacy, potential mechanisms, and implications for clinical practice. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched in Medline, Web of Science, Embase, ClinicalTrials.gov, CNKI, VIP, and WanFang databases using keywords ("probiotics" OR "prebiotics" OR "synbiotics" OR "Lactobacillus" OR "Bifidobacterium") AND ("schizophrenia"), focused on randomized controlled trials published before July 1, 2023. Among the identified studies, 8 randomized controlled trials met the inclusion criteria, encompassing a total of 342 participants in the intervention group and 306 participants in the control group. Our analysis revealed a statistically significant reduction (p = 0.03) in the total Positive and Negative Syndrome Scale (PANSS) scores following probiotic treatment in individuals with schizophrenia. While no statistical significance was observed in individual subscales (P > 0.05), significant improvements were noted in insulin levels, Insulin Resistance Index (IRI), and glucose levels. Additionally, the Quantitative Insulin Sensitivity Check Index (QUICKI) demonstrated a significant increase (all P < 0.05). The probiotic intervention significantly reduced gastrointestinal discomfort among schizophrenia patients (P = 0.003). This study suggests that probiotics could hold therapeutic potential for addressing clinical symptoms, abnormal glucose metabolism, and gastrointestinal discomfort in individuals with schizophrenia. Future research should encompass comparative trials employing robust experimental designs to explore the differential effects of various probiotic strains on schizophrenia treatment to provide evidence-based therapeutic approaches. Trial registration: This review protocol was pre-registered on PROSPERO (No. CRD42023455273). [ABSTRACT FROM AUTHOR]
Copyright of European Archives of Psychiatry & Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 186711333
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yang%2C+Mi%22&quot;&gt;Yang, Mi&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cui%2C+Xingxing%22&quot;&gt;Cui, Xingxing&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kong%2C+Di%22&quot;&gt;Kong, Di&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Huang%2C+Xincheng%22&quot;&gt;Huang, Xincheng&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zhao%2C+Guocheng%22&quot;&gt;Zhao, Guocheng&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Li%2C+Xiuying%22&quot;&gt;Li, Xiuying&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Zhao%2C+Huachang%22&quot;&gt;Zhao, Huachang&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Liu%2C+Liju%22&quot;&gt;Liu, Liju&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yan%2C+Fei%22&quot;&gt;Yan, Fei&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yang%2C+Yan%22&quot;&gt;Yang, Yan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Li%2C+Zezhi%22&quot;&gt;Li, Zezhi&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22European+Archives+of+Psychiatry+%26+Clinical+Neuroscience%22&quot;&gt;European Archives of Psychiatry &amp; Clinical Neuroscience&lt;/searchLink&gt;. Aug2025, Vol. 275 Issue 5, p1437-1451. 15p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Lactobacillus%22&quot;&gt;Lactobacillus&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Bifidobacterium%22&quot;&gt;Bifidobacterium&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Medical+practice%22&quot;&gt;Medical practice&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Probiotics%22&quot;&gt;Probiotics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%22&quot;&gt;Schizophrenia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Randomized+controlled+trials%22&quot;&gt;Randomized controlled trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Gut+microbiota%22&quot;&gt;Gut microbiota&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The modulation of gut microbiota through probiotics holds promise as a novel avenue for schizophrenia treatment. This study aims to analyze probiotic complementary therapy on individuals with schizophrenia systematically, to investigate probiotic efficacy, potential mechanisms, and implications for clinical practice. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we searched in Medline, Web of Science, Embase, ClinicalTrials.gov, CNKI, VIP, and WanFang databases using keywords (&quot;probiotics&quot; OR &quot;prebiotics&quot; OR &quot;synbiotics&quot; OR &quot;Lactobacillus&quot; OR &quot;Bifidobacterium&quot;) AND (&quot;schizophrenia&quot;), focused on randomized controlled trials published before July 1, 2023. Among the identified studies, 8 randomized controlled trials met the inclusion criteria, encompassing a total of 342 participants in the intervention group and 306 participants in the control group. Our analysis revealed a statistically significant reduction (p = 0.03) in the total Positive and Negative Syndrome Scale (PANSS) scores following probiotic treatment in individuals with schizophrenia. While no statistical significance was observed in individual subscales (P &gt; 0.05), significant improvements were noted in insulin levels, Insulin Resistance Index (IRI), and glucose levels. Additionally, the Quantitative Insulin Sensitivity Check Index (QUICKI) demonstrated a significant increase (all P &lt; 0.05). The probiotic intervention significantly reduced gastrointestinal discomfort among schizophrenia patients (P = 0.003). This study suggests that probiotics could hold therapeutic potential for addressing clinical symptoms, abnormal glucose metabolism, and gastrointestinal discomfort in individuals with schizophrenia. Future research should encompass comparative trials employing robust experimental designs to explore the differential effects of various probiotic strains on schizophrenia treatment to provide evidence-based therapeutic approaches. Trial registration: This review protocol was pre-registered on PROSPERO (No. CRD42023455273). [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of European Archives of Psychiatry &amp; Clinical Neuroscience is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=186711333
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00406-024-01935-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 15
        StartPage: 1437
    Subjects:
      – SubjectFull: Lactobacillus
        Type: general
      – SubjectFull: Bifidobacterium
        Type: general
      – SubjectFull: Medical practice
        Type: general
      – SubjectFull: Probiotics
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Gut microbiota
        Type: general
    Titles:
      – TitleFull: The efficacy of Lactobacillus and Bifidobacterium in patients with schizophrenia: a meta-analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yang, Mi
      – PersonEntity:
          Name:
            NameFull: Cui, Xingxing
      – PersonEntity:
          Name:
            NameFull: Kong, Di
      – PersonEntity:
          Name:
            NameFull: Huang, Xincheng
      – PersonEntity:
          Name:
            NameFull: Zhao, Guocheng
      – PersonEntity:
          Name:
            NameFull: Li, Xiuying
      – PersonEntity:
          Name:
            NameFull: Zhao, Huachang
      – PersonEntity:
          Name:
            NameFull: Liu, Liju
      – PersonEntity:
          Name:
            NameFull: Yan, Fei
      – PersonEntity:
          Name:
            NameFull: Yang, Yan
      – PersonEntity:
          Name:
            NameFull: Li, Zezhi
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09401334
          Numbering:
            – Type: volume
              Value: 275
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: European Archives of Psychiatry & Clinical Neuroscience
              Type: main
ResultId 1